Clinical Trials Logo

Large B Cell Diffuse Lymphoma clinical trials

View clinical trials related to Large B Cell Diffuse Lymphoma.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT03450343 Completed - Clinical trials for Large B-Cell Diffuse Lymphoma

Oral Azacitidine Plus Salvage Chemotherapy in Relapsed/Refractory Diffuse Large B Cell Lymphoma

Start date: April 4, 2019
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the safety and tolerability of adding oral azacitidine to the chemotherapy combination R-ICE. This study will also look at whether or not disease outcomes improve with the combination.

NCT ID: NCT01448096 Completed - Clinical trials for Large B Cell Diffuse Lymphoma

Study in Patients With Primary Breast Diffuse Large B-cell Lymphoma

Start date: August 2011
Phase: Phase 2
Study type: Interventional

The purpose of this study is to clarify the impact of rituximab on clinical outcomes in patients with primary breast diffuse large B-cell lymphoma and also to investigate the role of prophylactic intrathecal chemotherapy using methotrexate for reducing central nervous system (CNS) recurrence.

NCT ID: NCT01410630 Completed - Lymphoma Clinical Trials

FLT-PET/CT vs FDG-PET/CT for Therapy Monitoring of Diffuse Large B-cell Lymphoma

Start date: September 7, 2017
Phase:
Study type: Observational

A research study of a new method of visualizing internal organs called 18F-FLT PET/CT that yields better tracking of cancer treatment progress. PET/CT stands for positron emission tomography with low dose computed tomography and has been used for many years. 18F-FLT PET/CT uses a new tracer, fluorothymidine, which is taken up by cells that are actively proliferating or dividing such as cancer cells. We hope to learn whether this tracer is superior to the conventional tracer for monitoring treatment of diffuse large B-cell lymphoma (DLBCL).